Printer Friendly

MARROW-TECH RECEIVES APPROVAL TO FURTHER EXPAND DERMAGRAFT(TM) CLINICAL TRIALS

           MARROW-TECH RECEIVES APPROVAL TO FURTHER EXPAND
                   DERMAGRAFT(TM) CLINICAL TRIALS
    LA JOLLA, Calif., Nov. 6 /PRNewswire/ -- Marrow-Tech Inc. (NASDAQ-NMS: MAROA) today announced it has received approval from the Food and Drug Administration (FDA) to expand clinical trials of Dermagraft(TM) -- the company's living dermal replacement product -- from 12 to 24 burn centers.
    Marrow-Tech began clinical trials of Dermagraft for the treatment of burn patients at the University of California, San Diego Medical Center in January 1991 under an Investigational Device Exemption (IDE).  To date, more than 30 patients have been treated with Dermagraft at 10 burn centers across the country.  Preliminary clinical results were presented on Oct. 19 at the International Symposium on Wound Healing and Wound Management in Chicago.  The patients will be followed clinically to determine long-term graft outcomes and additional patients continue to be enrolled in the study.
    Concurrently, three leading wound care centers are participating in clinical trials of Dermagraft for the treatment of chronic venous skin ulcers under a supplemental IDE.  The company also plans to file for supplemental approval to treat patients with decubitus ulcers (pressure sores) by the end of this fiscal year.
    Marrow-Tech is engaged in the growth of the human tissue outside the body.  The company is developing its proprietary three- dimensional cell culture system for potential therapeutic and laboratory applications.
    -0-                      11/6/91
    /CONTACT:  Alana B. Wheeler of Marrow-Tech, 619-450-5714/
    (MAROA) CO:  Marrow-Tech Inc. ST:  California IN:  MTC SU: KJ-AL -- SD008 -- 1793 11/06/91 14:09 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 6, 1991
Words:249
Previous Article:McDONALD'S GOES TO TRIAL; THOUSANDS OF CHILDREN INJURED AT McDONALD'S PLAYGROUNDS NATIONWIDE, SAYS COHEN & STEINBRECHER
Next Article:BG&E AND HARFORD COUNTY ENTER COOPERATIVE AGREEMENT TO JOINTLY TAP BIG INCH WATER LINE
Topics:


Related Articles
ADVANCED TISSUE SCIENCES' DERMAGRAFT(TM) STUDIES PRESENTED AT BURN CONFERENCE
ADVANCED TISSUE SCIENCES REPORTS FULL YEAR RESULTS
ADVANCED TISSUE SCIENCES FILES TO EXPAND DERMAGRAFT(TM) CLINICAL TRIALS TO DIABETIC AND DECUBITUS ULCERS
ADVANCED TISSUE SCIENCES RECEIVES APPROVAL TO EXPAND DERMAGRAFT(TM) CLINICAL TRIALS TO DECUBITUS AND DIABETIC ULCERS
ADVANCED TISSUE SCIENCES AND MITSUBISHI KASEI ENTER AGREEMENT TO EVALUATE DERMAGRAFT(TM) FOR WOUND HEALING IN JAPAN
ADVANCED TISSUE SCIENCES ANNOUNCES FDA NOTIFICATION OF EXPEDITED REVIEW FOR DERMAGRAFT-TC(TM)
ADVANCED TISSUE SCIENCES RECEIVES FDA NOTIFICATION OF EXPEDITED REVIEW FOR DERMAGRAFT(R) IN THE TREATMENT OF DIABETIC FOOT ULCERS
Advanced Tissue Sciences Provides Dermagraft(R) Clinical Update
FDA Approves Treatment IDE for Dermagraft(R).

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters